corporate overview - gene technology - selexis · 12/5/2019 · corporate overview 4q 2019...
TRANSCRIPT
www.selexis.com
Quick Facts
CORPORATE OVERVIEW4Q 2019
Innovation Leader Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines.
Our global partners are utilizing Selexis technologies to advance more than 125 drug products in clinical development and the manufacture of six commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks.
Delivering Results In less than 20 years, the Selexis approach to cell line development and protein expression has already generated one of the most impressive portfolios of clinical and commercial cell lines producing a broad range of biotherapeutics from biosimilars to difficult-to-express proteins.1–5
1. SUREtechnology Platform™ Partner pipeline as of October 24, 20192. “Cell Line Development Market Size, Regional Analysis, Competitive Market Share & Forecast, 2023,” Global Markets Insights3. “Cell Line Development Market Analysis and Segment Forecasts 20 20202,” Grandview Research4. Internal research5. Data from third-party disclosures
Founded2001Employees50+HeadquartersGeneva, SwitzerlandStrong Patent Portfolio175 grantedSelexis is the top cell line development firm for number of technology advancements.1–3
Recent Milestones• Presented data at ESACT 2019
from the SUREtechnology and Beacon® Optofluidic collaboration, highlighting development of high-perfor-mance research cell banks (RCBs) in just eight weeks
• Joint SAB formation with KBI Biopharma, Inc.
• Expansion of EU laboratories, R&D unit, BD team
• Named one of Switzerland’s “Best Companies to Work for” in both 2018 and 2019
HeadquartersSelexis SA Chemin des Aulx, 14 1228 Plan les Ouates SWITZERLAND T +41 (0)22 308 93 60 Media Inquiries Kelly ConlonSam Brown Inc.+1 [email protected]
REV2019DEC05
129 DRUG CANDIDATES
6 MARKETEDPRODUCTS
Human Clinical Trials
Preclinical IND Filing Phase I Phase II Phase III Market
Autoimmune/Inflammatory 24 3 3 2 4 3
Blood Disorders 2 1 3 1
Cancer 31 12 21 11 1 2
Metabolic/Genetic 2 1 1 1
Dermatology/Eye 2
Infectious Diseases 1
Undisclosed 3
TOTAL 63 17 27 15 7 6
129 Clinical Candidates
Corporate Overview2Q 2019
Leadership Team
Licensing Opportunities
Igor Fisch, PhD Chief Executive Officer
Marco Bocci, PhD, DPharm Senior Vice President, European Licensing and Business Development
Regine Brokamp Chief Operating Officer
Alberto Garotti Chief Financial Officer
Pierre-Alain Girod, PhD Chief Scientific Officer
Yemi Onakunle, PhD, MBA Senior Vice President, US Licensing and Business Development
Selexis has breakthrough cell line development technologies that fundamentally impact and improve drug discovery, development and biopharmaceutical manufacturing.
To discuss business development opportunities, please contact our technology licensing and business development liaison: Déborah Ley, PhD [email protected]
Redefining Best-in-Class Cell Line Development TechnologySelexis’ innovation and expertise have driven the development and ongoing optimization of the most robust and flexible cell line-based protein expression platform in the industry — the SUREtechnology Platform™.
Genome andTranscriptome
Advanced GeneTransfection
Technology andProcedures
ProprietaryCHO-K1Cell Line
Media andFeed Strategies
SURE CHO-MplusLibraries™SUREscan®
SUREsignature™
SUREfeed Strategy™Off-The-Shelf MediaOff-The-Shelf Feed
Selexis SGE®
(Selexis Genetic Elements)SUREtech Vectors™SUREfection Procedures™SUREvariant Screening™
Selexis SURECHO-M Cell Line™(CHO-K1)
Our PromiseHighest yield and stable research cell banks
De-risk regulatory issues while maintaining speed, high productivity and stability
Rescue programs lost due to poor expression
Decrease attrition rates in biologics (lead generation)
Unique documentation fully traceable research cell banks
Continually provide breakthrough technologies
to fundamentally improve the discovery, development and
manufacturing of biologic therapies and vaccines.
Our Mission
REV2019DEC05
Innovation, safety and new therapies impacting
patients’ quality of life
Our Values
Innovative technologies for the rapid development and engineering of clonal
mammalian research cell banks (RCBs)
Full research cell bank documentation with genome characterization, traceability
and “clonality” reports
Our Focus